Editorial Material
Immunology
Preston A. Humphries, Wan-Lin Lo
Summary: A new study reveals the differential binding manner of CTLA-4 to CD80 and CD86, which plays a crucial role in immune tolerance regulation.
Article
Gastroenterology & Hepatology
Cathrin L. C. Gudd, Lewis Au, Evangelos Triantafyllou, Benjamin Shum, Tong Liu, Rooshi Nathwani, Naveenta Kumar, Sujit Mukherjee, Ameet Dhar, Kevin J. Woollard, You Yone, David J. Pinato, Mark R. Thursz, Robert D. Goldin, Martin E. Gore, James Larkin, Wafa Khamri, Charalambos G. Antoniades, Samra Turajlic, Lucia A. Possamai
Summary: This study reveals that patients with checkpoint inhibitor-related hepatitis exhibit activation of peripheral monocytes and an enhanced cytotoxic, effector CD8(+) T cell phenotype, with the presence of CD163(+)CCR2(+) macrophages and CD8(+) T cells in liver tissue. Targeting these pathways identified in the study may help prevent or manage liver-related side effects of immunotherapy.
JOURNAL OF HEPATOLOGY
(2021)
Article
Oncology
Mathilde Beaufils, Vincent Amodru, Manuel Tejeda, Jean Marie Boher, Christophe Zemmour, Brice Chanez, Anne Sophie Chretien, Laurent Gorvel, Gwenaelle Gravis, Damien Bruyat, Roxane Mari, Anne Madroszyk, Thomas Cuny, Anthony Goncalves, Aaron E. Lisberg, Daniel Olive, Louis Tassy, Frederic Castinetti, Philippe Rochigneux
Summary: Data mining analysis showed that immune checkpoint inhibitor (ICI)-induced dysthyroidism (DT) was associated with improved overall survival (OS), and patients with both DT and other immune-related adverse events had even longer OS.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Pharmacology & Pharmacy
Bingjian Wen, Chengcheng Zhang, Jingwen Zhou, Zhengyan Zhang, Qishi Che, Hua Cao, Yan Bai, Jiao Guo, Zhengquan Su
Summary: Targeted therapy is important in treating alcoholic liver disease (ALD) and hepatocellular carcinoma (HCC), with inflammation playing a crucial role in both diseases. Combination therapy with inhibitors of inflammatory pathways and immune checkpoint inhibitors has shown promising results in mouse models of HCC.
PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Biochemistry & Molecular Biology
Fatimat Kipkeeva, Tatyana Muzaffarova, Alexandra Korotaeva, Danzan Mansorunov, Pavel Apanovich, Maxim Nikulin, Olga Malikhova, Ivan Stilidi, Alexander Karpukhin
Summary: MiRNAs, which influence IC gene expression in tumor and T-cells, show potential as agents for cancer immunotherapy with tumor specificity. Further research on miRNA-gene interaction features and optimal miRNA mimic structure is necessary.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Marije J. Voskamp, Shuang Li, Kim R. van Daalen, Sandra Crnko, Toine ten Broeke, Niels Bovenschen
Summary: Medulloblastoma (MB), a primary brain tumor in children, is commonly treated with surgery, radiotherapy, and chemotherapy, but these methods often lead to severe brain damage and high relapse rates. Immunotherapy has emerged as a potential alternative, with a focus on immune checkpoint inhibition and CAR T-cell therapy, and research in this area is ongoing to improve treatment outcomes.
Article
Oncology
Arta M. Monjazeb, Ziming Wang, Logan V. Vick, Cordelia Dunai, Christine Minnar, Lam T. Khuat, William J. Murphy
Summary: The study emphasizes the importance of using species appropriate reagents to evaluate the efficacy and toxicity of cancer immunotherapy in mouse models. The use of a mouse anti-mouse PD-1 antibody can prevent lethal anaphylaxis and show superior antitumor effects compared to xenogeneic reagents.
Review
Oncology
Steven Nicolaides, Alex Boussioutas
Summary: Immunotherapy is an effective cancer treatment that activates the immune system to target and destroy cancer cells. However, the use of immune checkpoint inhibitors is often limited by immune-related adverse events. This review focuses on the management and emerging therapies for immune-related adverse events in the gastrointestinal system.
Article
Oncology
Rom Leidner, Kevin Conlon, Douglas G. Mcneel, Andrea Wang-Gillam, Sumati Gupta, Robert Wesolowski, Monica Chaudhari, Nadia Hassounah, Jong Bong Lee, Lang Ho Lee, Jessica A. O'Keeffe, Nancy Lewis, George N. Pavlakis, John A. Thompson
Summary: This study investigated the efficacy and safety of NIZ985 as monotherapy and in combination with spartalizumab in the treatment of advanced solid tumors. The results showed that NIZ985 demonstrated antitumor activity and was well tolerated in patients with advanced solid tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Ming Zheng
Summary: This study demonstrates that the neutrophil-to-lymphocyte ratio (NLR) is a valuable indicator for predicting the outcomes of immune checkpoint blockade (ICB) treatment. An NLR range of 2.0 to 3.0 is associated with optimal treatment outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Chemistry, Multidisciplinary
Chi Zhang, Mengke Xu, Shasha He, Jingsheng Huang, Cheng Xu, Kanyi Pu
Summary: This study reports the use of checkpoint nano-PROTACs combined with photodynamic tumor regression and immunosuppressive protein degradation to block checkpoint signaling pathways for activatable cancer photo-immunotherapy. The nano-PROTACs consist of a photosensitizer and an SHP2-targeting PROTAC peptide connected by a caspase 3-cleavable segment. By degrading SHP2, these nano-PROTACs can block immunosuppressive checkpoint signaling pathways and enhance antitumor immune response. This study represents a generalized PROTAC platform to modulate immune-related signaling pathways for improved anticancer therapy.
ADVANCED MATERIALS
(2023)
Review
Chemistry, Multidisciplinary
Haifen Luo, Wen Ma, Qi Chen, Zhen Yang, Yunlu Dai
Summary: Radiotherapy can induce immune responses in the tumor microenvironment, but it can also increase immune suppressor cells, limiting its effectiveness. Nanomedicine can deliver immunoadjuvants to block immune suppression and improve the combination of radiotherapy and immunotherapy.
Article
Chemistry, Multidisciplinary
Adam A. Walters, Gemma Santacana-Font, Jin Li, Nadia Routabi, Yue Qin, Nathalie Claes, Sara Bals, Julie Tzu-Wen Wang, Khuloud T. Al-Jamal
Summary: The study demonstrates that a combination of siRNA and mRNA in a single formulation can simultaneously reduce and induce expression of immune checkpoint targets to reprogram the tumor microenvironment. Using SNALPs, efficient transfection of cells with minimal toxicity was achieved in vitro.
Article
Oncology
Anne Zaremba, Peter Mohr, Ralf Gutzmer, Friedegund Meier, Claudia Pfoehler, Michael Weichenthal, Patrick Terheyden, Andrea Forschner, Ulrike Leiter, Jens Ulrich, Jochen Utikal, Julia Welzel, Martin Kaatz, Christoffer Gebhardt, Rudolf Herbst, Anca Sindrilaru, Edgar Dippel, Michael Sachse, Frank Meiss, Lucie Heinzerling, Sebastian Haferkamp, Carsten Weishaupt, Harald Loeffler, Sophia Kreft, Klaus Griewank, Elisabeth Livingstone, Dirk Schadendorf, Selma Ugurel, Lisa Zimmer
Summary: This study analyzed the impact of NRAS gene mutations on melanoma patients treated with immune checkpoint inhibitors. The results showed that NRAS mutations were not significantly correlated with patients' survival and treatment response, and had no correlation with the expression of the T-cell immune checkpoint molecule PD-L1.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Immunology
Rui Rui, Liqun Zhou, Shiming He
Summary: Immunotherapy has revolutionized cancer treatment, with ongoing advancements. The aim of cancer immunotherapy is to activate the host immune system to fight against malignant tumors. Tumor infiltrating leukocytes play a role in tumor microenvironment and their interaction with tumor cells influences tumor progression. Various immunotherapies, such as immune checkpoint inhibitors, cancer vaccines, and adoptive cell transfer, have shown promising efficacy. This review summarizes the recent research progress in tumor immunotherapy, including molecular mechanisms, clinical effects, and limitations.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Physiology
Antonio Riva, Elena Palma, Dhruti Devshi, Douglas Corrigall, Huyen Adams, Nigel Heaton, Krishna Menon, Melissa Preziosi, Ane Zamalloa, Rosa Miquel, Jennifer M. Ryan, Gavin Wright, Sarah Fairclough, Alexander Evans, Debbie Shawcross, Robert Schierwagen, Sabine Klein, Frank E. Uschner, Michael Praktiknjo, Krum Katzarov, Tanya Hadzhiolova, Slava Pavlova, Marieta Simonova, Jonel Trebicka, Roger Williams, Shilpa Chokshi
Summary: The study found that patients with alcohol-related liver disease exhibit abnormally elevated levels of soluble TIM3, especially those with more severe conditions. Soluble TIM3 is strongly correlated with pro-inflammatory cytokines, gut bacterial translocation markers, and disease severity indicators. In addition, bacterial challenge leads to the overexpression of membrane TIM3 on immune cells.
FRONTIERS IN PHYSIOLOGY
(2021)
Review
Substance Abuse
Natalia A. Osna, Moses New-Aaron, Raghubendra S. Dagur, Paul Thomes, Liz Simon, Danielle Levitt, Patrick McTernan, Patricia E. Molina, Hye Yeon Choi, Keigo Machida, Kenneth E. Sherman, Antonio Riva, Sandra Phillips, Shilpa Chokshi, Kusum K. Kharbanda, Steven Weinman, Murali Ganesan
Summary: The article discusses the exacerbating effects of alcohol on viral infections and the underlying mechanisms, focusing on the immune and metabolic changes in hepatotropic viral infections, as well as the interactions between viruses and alcohol.
ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH
(2022)
Review
Gastroenterology & Hepatology
Sophie Lotersztajn, Antonio Riva, Sai Wang, Steven Dooley, Shilpa Chokshi, Bin Gao
Summary: Chronic alcohol consumption leads to stress and damage in liver cells, causing inflammation and fibrosis. Alcohol also disrupts intestinal barrier function and leads to gut microbial imbalance, indirectly causing inflammation in the liver. The current standard treatment for severe alcoholic hepatitis is prednisolone, but it only provides short-term improvement in survival rates and increases the risk of bacterial infections. Recent studies focus on finding more specific targets for inflammation to treat this liver disease effectively.
ZEITSCHRIFT FUR GASTROENTEROLOGIE
(2022)
Article
Endocrinology & Metabolism
Ewald Jan Doornebal, Nicola Harris, Antonio Riva, Ravi Jagatia, Michail Pizanias, Andreas Prachalias, Krishna Menon, Melissa Preziosi, Ane Zamalloa, Rosa Miquel, Yoh Zen, Michael Robert Orford, Simon Eaton, Nigel Heaton, John Ramage, Elena Palma, Rajaventhan Srirajaskanthan, Shilpa Chokshi
Summary: This article describes the development of a personalised immunocompetent precision cut tumour slice (PCTS) model for neuroendocrine liver metastases (LM-NEN). The model preserves cellular heterogeneity and clinical features of the original tumour and provides a powerful platform for investigating tumor pathways and conducting mechanistic, immunological, and pre-clinical studies.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Editorial Material
Immunology
Antonio Riva
FRONTIERS IN IMMUNOLOGY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Sara Campinoti, Claire McQuitty, Lorenzo Caciolli, Bruna Almeida, Lai Wei, Luca Zanieri, Antonio Riva, Alessandro F. Pellegata, Paola Bonfanti, Sara Mantero, Shilpa Chokshi, Luca Urbani
JOURNAL OF HEPATOLOGY
(2022)
Meeting Abstract
Gastroenterology & Hepatology
Dhruti Devshi, Sandra Phillips, Helen Edwards, Nicola Harris, Melissa Preziosi, Abid Suddle, Antonio Riva, Shilpa Chokshi
JOURNAL OF HEPATOLOGY
(2022)
Meeting Abstract
Gastroenterology & Hepatology
Elena Palma, Nicola Harris, Una Rastovic, Tsin Shue Koay, Ewald Doornebal, Sandra Phillips, Antonio Riva, Daren Ure, Rosa Miquel, Melissa Preziosi, Andreas Prachalias, Krishna Menon, Nigel Heaton, Roger Williams, Shilpa Chokshi
JOURNAL OF HEPATOLOGY
(2021)
Meeting Abstract
Gastroenterology & Hepatology
Jennifer M. Ryan, Huyen Li Adams, Dhruti Devshi, Stephen Atkinson, Luke Tyson, Debbie L. Shawcross, Gavin Wright, Sarah Fairclough, Alex Evans, Marieta Simonova, Krum Katzarov, Tanya Hadzhiolova, Slava Pavlova, Jasmohan Bajaj, Andrew Fagan, Mark Thursz, Roger Williams, Andrew McQuillin, Marsha Y. Morgan, Antonio Riva, Shilpa Chokshi
JOURNAL OF HEPATOLOGY
(2021)
Meeting Abstract
Gastroenterology & Hepatology
Vishal C. Patel, Elizabeth H. Gray, Antonio Riva, Sarah Azarian, Mark J. W. McPhail, Roger Williams, Shilpa Chokshi, Lindsey Edwards
JOURNAL OF HEPATOLOGY
(2020)
Meeting Abstract
Gastroenterology & Hepatology
Sandra Phillips, Sameer Mistry, Jason Coombes, Tanya Hadzhiolova, Ewald Doornebal, Nicola Harris, Elena Palma, Antonio Riva, Slava Pavlova, Marieta Simonova, Luca Urbani, Lola Ajayi, Dipa Natarajan, Krum Katzarov, Krishna Menon, Andreas Prachalias, Parthi Srinivasan, Nigel Heaton, Michail Pizanias, Ane Zamalloa, Melissa Preziosi, Yoh Zen, Rosa Miquel, Corina Cotoi, Maesha Deheragoda, Caroline Robinson, Patrick Kennedy, Upkar Gill, Thiago A. Pereira, Fausto Edmundo Pereira, Roger Williams, Wing Syn, Shilpa Chokshi
JOURNAL OF HEPATOLOGY
(2020)
Meeting Abstract
Gastroenterology & Hepatology
Douglas Corrigall, Nicola Harris, Dhruti Devshi, Sarah Fairclough, Gavin Wright, Jonel Trebicka, Carlo Alessandria, Paolo Angeli, Rajiv Jalan, Joan Claria, Richard Moreau, Vicente Arroyo, Roger Williams, Antonio Riva, Shilpa Chokshi
JOURNAL OF HEPATOLOGY
(2020)
Meeting Abstract
Gastroenterology & Hepatology
Antonio Riva, Jasmohan S. Bajaj, Andrew Fagan, Roger Williams, Shilpa Chokshi
JOURNAL OF HEPATOLOGY
(2020)
Meeting Abstract
Gastroenterology & Hepatology
Antonio Riva, Douglas Corrigall, Huyen Adams, Nicola Harris, Yong Xin Sieh, Gavin Wright, Sarah Fairclough, Alex Evans, Debbie L. Shawcross, Marieta Simonova, Tanya Hadzhiolova, Slava Pavlova, Krum Katzarov, Roger Williams, Shilpa Chokshi
JOURNAL OF HEPATOLOGY
(2020)
Meeting Abstract
Gastroenterology & Hepatology
Jennifer Ryan, Huyen Adams, Stephen Atkinson, Luke D. Tyson, Sarah Fairclough, Gavin Wright, Alex Evans, Jasmohan S. Bajaj, Andrew Fagan, Debbie L. Shawcross, Mark Thursz, McQuillan Andrew, Marsha Morgan, Roger Williams, Antonio Riva, Shilpa Chokshi
JOURNAL OF HEPATOLOGY
(2020)